Half of the participants received the drug while other half got a placebo.
"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently. It could mean many months more of recognizing their spouse, children and grandchildren," the U.S.-based Alzheimer's Association said Tuesday in a statement.
"Treatments that deliver tangible benefits to those living with mild cognitive impairment (MCI) due to Alzheimer's and early Alzheimer's dementia are as valuable as treatments that extend the lives of those with other terminal diseases," the group added.
Currently, more than 55 million people live with dementia worldwide, and this number is estimated to reach 78 million by 2030 and 139 million by 2050, according to the World Health Organization.
